Please wait

Exhibit 23.1

 

 

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

 

1.
Registration Statement (Form S-3 No. 333-282460) of Neumora Therapeutics, Inc.
2.
Registration Statement (Form S-8 No. 333-277748) pertaining to 2023 Incentive Award Plan and 2023 Employee Stock Purchase Plan of Neumora Therapeutics, Inc.,
3.
Registration Statement (Form S-8 No. 333-274593) pertaining to the Blackthorn Therapeutics, Inc. 2015 Equity Incentive Plan, 2020 Equity Incentive Plan, 2023 Incentive Award Plan, and Employee Stock Purchase Plan of Neumora Therapeutics, Inc.,

 

of our reports dated March 3, 2025, with respect to the consolidated financial statements of Neumora Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Neumora Therapeutics, Inc. included in this Annual Report (Form 10-K) of Neumora Therapeutics, Inc. for the year ended December 31, 2024.

 

/s/ Ernst & Young LLP

 

San Jose, California

March 3, 2025